A 12-month study to investigate the efficacy, safety and pharmacokinetics of a monthly dosing regimen of ranibizumab (0.5 mg) in combination with pegpleranib (1.5mg), compared to monthly raranibizumab (0.5 mg) monotherapy, in patients with nAMD
Research Grant
Administered By
Ophthalmology
Awarded By
Novartis Pharma AG
Start Date
October 1, 2016
End Date
December 14, 2016
Administered By
Ophthalmology
Awarded By
Novartis Pharma AG
Start Date
October 1, 2016
End Date
December 14, 2016